The neuronal influence on tumor progression

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1816, Issue 2, 2011, Pages 105-118

  Mancino, Mario ^a   Ametller, Elisabet ^a   Gascón, Pedro ^a   Almendro, Vanessa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Axon guidance molecules; Cancer progression; Neoneurogenesis; Neuropeptides; Neurotransmitters; Neurotrophic factors; Perineural invasion

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADRENALIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; EPHRIN; FIBROBLAST GROWTH FACTOR; GLUTAMIC ACID; MUSCARINIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NETRIN; NETRIN RECEPTOR; NEUROPEPTIDE; NEUROTROPHIC FACTOR; NEUROTROPHIN 1; NEUROTROPHIN 3; NICOTINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR; SEMAPHORIN; SEROTONIN; TACHYKININ; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL SURVIVAL; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MORPHOGENESIS; NERVE ENDING; NERVE FIBER GROWTH; NERVOUS SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NERVOUS TISSUE; NEUROANATOMY; NEUROMODULATION; NONHUMAN; PERINEURIUM; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79957967279     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.04.005     Document Type: Review

References (241)

1. A. Marusyk, K. Polyak, Tumor heterogeneity: causes and consequences, Biochim. Biophys. Acta 1805 (2010) 105-117.
2. J. Folkman, E. Merler, C. Abernathy, G. Williams, Isolation of a tumor factor responsible for angiogenesis, J. Exp. Med. 133 (1971) 275-288.
3. C. Fischer, B. Jonckx, M. Mazzone, S. Zacchigna, S. Loges, L. Pattarini, E. Chorianopoulos, L. Liesenborghs, M. Koch, M. De Mol, M. Autiero, S. Wyns, S. Plaisance, L. Moons, N. van Rooijen, M. Giacca, J.M. Stassen, M. Dewerchin, D. Collen, P. Carmeliet, Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels, Cell 131 (2007) 463-475.
4. C. Fischer, M. Mazzone, B. Jonckx, P. Carmeliet, FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat. Rev. Cancer 8 (2008) 942-956.
5. L.M. Ellis, D.J. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nat. Rev. Cancer 8 (2008) 579-591.
6. R.K. Jain, D.G. Duda, J.W. Clark, J.S. Loeffler, Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nat. Clin. Pract. Oncol. 3 (2006) 24-40.
7. G. Bergers, D. Hanahan, Modes of resistance to anti-angiogenic therapy, Nat. Rev. Cancer 8 (2008) 592-603.
8. K. Alitalo, T. Tammela, T.V. Petrova, Lymphangiogenesis in development and human disease, Nature 438 (2005) 946-953.
9. Y. He, I. Rajantie, K. Pajusola, M. Jeltsch, T. Holopainen, S. Yla-Herttuala, T. Harding, K. Jooss, T. Takahashi, K. Alitalo, Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels, Cancer Res. 65 (2005) 4739-4746.
10. M.G. Achen, S.A. Stacker, Tumor lymphangiogenesis and metastatic spread-new players begin to emerge, Int. J. Cancer 119 (2006) 1755-1760.
11. S.A. Stacker, M.E. Baldwin, M.G. Achen, The role of tumor lymphangiogenesis in metastatic spread, FASEB J. 16 (2002) 922-934.
12. C. Orellana, Is lymphangiogenesis as important as angiogenesis? Lancet Oncol. 6 (2005) 265.
13. P. Seifert, M. Benedic, P. Effert, Nerve fibers in tumors of the human urinary bladder, Virchows Arch. 440 (2002) 291-297.
14. P. Seifert, M. Spitznas, Tumours may be innervated, Virchows Arch. 438 (2001) 228-231.
15. P. Seifert, M. Spitznas, Axons in human choroidal melanoma suggest the participation of nerves in the control of these tumors, Am. J. Ophthalmol. 133 (2002) 711-713.
16. S. Ventura, J. Pennefather, F. Mitchelson, Cholinergic innervation and function in the prostate gland, Pharmacol. Ther. 94 (2002) 93-112.
17. B.S. Mitchell, U. Schumacher, V.V. Stauber, E. Kaiserling, Are breast tumours innervated? Immunohistological investigations using antibodies against the neuronal marker protein gene product 9.5 (PGP 9.5) in benign and malignant breast lesions, Eur. J. Cancer 30A (1994) 1100-1103.
18. W.Y. Tsang, J.K. Chan, Neural invasion in intraductal carcinoma of the breast, Hum. Pathol. 23 (1992) 202-204.
19. M. Kayahara, H. Nakagawara, H. Kitagawa, T. Ohta, The nature of neural invasion by pancreatic cancer, Pancreas 35 (2007) 218-223.
20. B.S. Mitchell, U. Schumacher, E. Kaiserling, Are tumours innervated? Immunohistological investigations using antibodies against the neuronal marker protein gene product 9.5 (PGP 9.5) in benign, malignant and experimental tumours, Tumour Biol. 15 (1994) 269-274.
21. S.H. Lu, Y. Zhou, H.P. Que, S.J. Liu, Peptidergic innervation of human esophageal and cardiac carcinoma, World J. Gastroenterol. 9 (2003) 399-403.
22. G.E. Ayala, T.M. Wheeler, H.D. Shine, M. Schmelz, A. Frolov, S. Chakraborty, D. Rowley, In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer, Prostate 49 (2001) 213-223.
23. J.P. Godbout, R. Glaser, Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer, J. Neuroimmune Pharmacol. 1 (2006) 421-427.
24. P.H. Thaker, L.Y. Han, A.A. Kamat, J.M. Arevalo, R. Takahashi, C. Lu, N.B. Jennings, G. Armaiz-Pena, J.A. Bankson, M. Ravoori, W.M. Merritt, Y.G. Lin, L.S. Mangala, T.J. Kim, R.L. Coleman, C.N. Landen, Y. Li, E. Felix, A.M. Sanguino, R.A. Newman, M. Lloyd, D.M. Gershenson, V. Kundra, G. Lopez-Berestein, S.K. Lutgendorf, S.W. Cole, A.K. Sood, Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma, Nat. Med. 12 (2006) 939-944.
25. J.W. Lee, M.M. Shahzad, Y.G. Lin, G. Armaiz-Pena, L.S. Mangala, H.D. Han, H.S. Kim, E.J. Nam, N.B. Jennings, J. Halder, A.M. Nick, R.L. Stone, C. Lu, S.K. Lutgendorf, S.W. Cole, A.E. Lokshin, A.K. Sood, Surgical stress promotes tumor growth in ovarian carcinoma, Clin. Cancer Res. 15 (2009) 2695-2702.
26. K. Lang, T.L.t. Drell, A. Lindecke, B. Niggemann, C. Kaltschmidt, K.S. Zaenker, F. Entschladen, Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs, Int. J. Cancer 112 (2004) 231-238.
27. F. Entschladen, T.L.t. Drell, K. Lang, J. Joseph, K.S. Zaenker, Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters, Lancet Oncol. 5 (2004) 254-258.
28. P. Grabowski, I. Schindler, I. Anagnostopoulos, H.D. Foss, E.O. Riecken, U. Mansmann, H. Stein, G. Berger, H.J. Buhr, H. Scherubl, Neuroendocrine differentiation is a relevant prognostic factor in stage III - IV colorectal cancer, Eur. J. Gastroenterol. Hepatol. 13 (2001) 405-411.
29. L. Dolle, I. El Yazidi-Belkoura, E. Adriaenssens, V. Nurcombe, H. Hondermarck, Nerve growth factor overexpression and autocrine loop in breast cancer cells, Oncogene 22 (2003) 5592-5601.
30. A.A. Geldof, E.P. Van Haarst, D.W. Newling, Neurotrophic factors in prostate and prostatic cancer, Prostate Cancer Prostatic Dis. 1 (1998) 236-241.
31. A. Ricci, S. Greco, S. Mariotta, L. Felici, E. Bronzetti, A. Cavazzana, G. Cardillo, F. Amenta, A. Bisetti, G. Barbolini, Neurotrophins and neurotrophin receptors in human lung cancer, Am. J. Respir. Cell Mol. Biol. 25 (2001) 439-446.
32. A. Chedotal, G. Kerjan, C. Moreau-Fauvarque, The brain within the tumor: new roles for axon guidance molecules in cancers, Cell Death Differ. 12 (2005) 1044-1056.
33. J.G. Batsakis, Nerves and neurotropic carcinomas, Ann. Otol. Rhinol. Laryngol. 94 (1985) 426-427.
34. C. Liebig, G. Ayala, J.A. Wilks, D.H. Berger, D. Albo, Perineural invasion in cancer: a review of the literature, Cancer 115 (2009) 3379-3391.
35. A.E. Rodin, D.L. Larson, D.K. Roberts, Nature of the perineural space invaded by prostatic carcinoma, Cancer 20 (1967) 1772-1779.
36. G.O. Ceyhan, F. Liebl, M. Maak, T. Schuster, K. Becker, R. Langer, I.E. Demir, M. Hartel, H. Friess, R. Rosenberg, The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy, Ann. Surg. 252 (2010) 797-804.
37. G.E. Ayala, H. Dai, M. Ittmann, R. Li, M. Powell, A. Frolov, T.M. Wheeler, T.C. Thompson, D. Rowley, Growth and survival mechanisms associated with perineural invasion in prostate cancer, Cancer Res. 64 (2004) 6082-6090.
38. H. Dai, R. Li, T. Wheeler, M. Ozen, M. Ittmann, M. Anderson, Y. Wang, D. Rowley, M. Younes, G.E. Ayala, Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach, Hum. Pathol. 38 (2007) 299-307.
39. H. Arakawa, Netrin-1 and its receptors in tumorigenesis, Nat. Rev. Cancer 4 (2004) 978-987.
40. J.L. Bixby, W.A. Harris, Molecular mechanisms of axon growth and guidance, Annu. Rev. Cell Biol. 7 (1991) 117-159.
41. H.T. Park, J. Wu, Y. Rao, Molecular control of neuronal migration, Bioessays 24 (2002) 821-827.
42. K.J. Tomaselli, L.F. Reichardt, J.L. Bixby, Distinct molecular interactions mediate neuronal process outgrowth on non-neuronal cell surfaces and extracellular matrices, J. Cell Biol. 103 (1986) 2659-2672.
43. J.L. Bixby, R.S. Pratt, J. Lilien, L.F. Reichardt, Neurite outgrowth on muscle cell surfaces involves extracellular matrix receptors as well as Ca2+ -dependent and -independent cell adhesion molecules, Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 2555-2559.
44. D.A. Tonge, J.P. Golding, M. Edbladh, M. Kroon, P.E. Ekstrom, A. Edstrom, Effects of extracellular matrix components on axonal outgrowth from peripheral nerves of adult animals in vitro, Exp. Neurol. 146 (1997) 81-90.
45. R.J. Giger, E.R. Hollis 2nd, M.H. Tuszynski, Guidance molecules in axon regeneration, Cold Spring Harb. Perspect. Biol. 2 (2010) a001867.
46. F. Polleux, W. Snider, Initiating and growing an axon, Cold Spring Harb. Perspect. Biol. 2 (2010) a001925.
47. J.L. Bixby, P. Jhabvala, Extracellular matrix molecules and cell adhesion molecules induce neurites through different mechanisms, J. Cell Biol. 111 (1990) 2725-2732.
48. A. Scuteri, M. Miloso, D. Foudah, M. Orciani, G. Cavaletti, G. Tredici, Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair? Curr. Stem Cell Res. Ther. 6 (2011) 82-92.
49. L. Ricci-Vitiani, R. Pallini, M. Biffoni, M. Todaro, G. Invernici, T. Cenci, G. Maira, E.A. Parati, G. Stassi, L.M. Larocca, R. De Maria, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, Nature 468 (2010) 824-828.
50. A. Kruttgen, I. Schneider, J. Weis, The dark side of the NGF family: neurotrophins in neoplasias, Brain Pathol. 16 (2006) 304-310.
51. E. Adriaenssens, E. Vanhecke, P. Saule, A. Mougel, A. Page, R. Romon, V. Nurcombe, X. Le Bourhis, H. Hondermarck, Nerve growth factor is a potential therapeutic target in breast cancer, Cancer Res. 68 (2008) 346-351.
52. R.J. Warrington, K.E. Lewis, Natural Antibodies Against Nerve Growth Factor Inhibit In Vitro Prostate Cancer Cell Metastasis, Cancer Immunol. Immunother. 60 (2011) 187-195.
53. W.G. Mantyh, J.M. Jimenez-Andrade, J.I. Stake, A.P. Bloom, M.J. Kaczmarska, R.N. Taylor, K.T. Freeman, J.R. Ghilardi, M.A. Kuskowski, P.W. Mantyh, Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain, Neuroscience 171 (2010) 588-598.
54. J.R. Ghilardi, K.T. Freeman, J.M. Jimenez-Andrade, W.G. Mantyh, A.P. Bloom, M.A. Kuskowski, P.W. Mantyh, Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain, Mol. Pain 6 (2010) 87.
55. M. Hofer, S.R. Pagliusi, A. Hohn, J. Leibrock, Y.A. Barde, Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain, EMBO J. 9 (1990) 2459-2464.
56. R.F. Alderson, A.L. Alterman, Y.A. Barde, R.M. Lindsay, Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture, Neuron 5 (1990) 297-306.
57. B. Connor, D. Young, Q. Yan, R.L. Faull, B. Synek, M. Dragunow, Brain-derived neurotrophic factor is reduced in Alzheimer's disease, Brain Res. Mol. Brain Res. 49 (1997) 71-81.
58. Z.F. Yang, D.W. Ho, C.T. Lam, J.M. Luk, C.T. Lum, W.C. Yu, R.T. Poon, S.T. Fan, Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma, Cancer Res. 65 (2005) 219-225.
59. E. Bronzetti, M. Artico, F. Forte, G. Pagliarella, L.M. Felici, A. D'Ambrosio, G. Vespasiani, B. Bronzetti, A possible role of BDNF in prostate cancer detection, Oncol. Rep. 19 (2008) 969-974.
60. P.C. Lai, T.H. Chiu, Y.T. Huang, Overexpression of BDNF and TrkB in human bladder cancer specimens, Oncol. Rep. 24 (2010) 1265-1270.
61. P.E. Zage, T.C. Graham, L. Zeng, W. Fang, C. Pien, K. Thress, C. Omer, J.L. Brown, P.A. Zweidler-McKay, The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan, Cancer 117 (2011) 1321-1391.
62. G. Senaldi, B.C. Varnum, U. Sarmiento, C. Starnes, J. Lile, S. Scully, J. Guo, G. Elliott, J. McNinch, C.L. Shaklee, D. Freeman, F. Manu, W.S. Simonet, T. Boone, M.S. Chang, Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11458-11463.
63. Y. Shi, W. Wang, P.A. Yourey, S. Gohari, D. Zukauskas, J. Zhang, S. Ruben, R.F. Alderson, Computational EST database analysis identifies a novel member of the neuropoietic cytokine family, Biochem. Biophys. Res. Commun. 262 (1999) 132-138.
64. T. Kishimoto, S. Akira, M. Narazaki, T. Taga, Interleukin-6 family of cytokines and gp130, Blood 86 (1995) 1243-1254.
65. R. Burger, F. Bakker, A. Guenther, W. Baum, D. Schmidt-Arras, T. Hideshima, Y.T. Tai, R. Shringarpure, L. Catley, G. Senaldi, M. Gramatzki, K.C. Anderson, Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival, Br. J. Haematol. 123 (2003) 869-878.
66. L.F. Reichardt, Neurotrophin-regulated signalling pathways, Philos. Trans. R. Soc. Lond. B Biol. Sci. 361 (2006) 1545-1564.
67. T. Ohta, M. Numata, Y. Tsukioka, F. Futagami, M. Kayahara, H. Kitagawa, T. Nagakawa, M. Yamamoto, T. Wakayama, Y. Kitamura, T. Terada, Y. Nakanuma, Neurotrophin-3 expression in human pancreatic cancers, J. Pathol. 181 (1997) 405-412.
68. F. Truzzi, A. Marconi, R. Lotti, K. Dallaglio, L.E. French, B.L. Hempstead, C. Pincelli, Neurotrophins and their receptors stimulate melanoma cell proliferation and migration, J. Invest. Dermatol. 128 (2008) 2031-2040.
69. L.M. McGregor, B.K. McCune, J.R. Graff, P.R. McDowell, K.E. Romans, G.D. Yancopoulos, D.W. Ball, S.B. Baylin, B.D. Nelkin, Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4540-4545.
70. Z. Zhu, H. Friess, F.F. diMola, A. Zimmermann, H.U. Graber, M. Korc, M.W. Buchler, Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer, J. Clin. Oncol. 17 (1999) 2419-2428.
71. A.T. Weeraratna, J.T. Arnold, D.J. George, A. DeMarzo, J.T. Isaacs, Rational basis for Trk inhibition therapy for prostate cancer, Prostate 45 (2000) 140-148.
72. B. Davidson, R. Reich, P. Lazarovici, J.M. Nesland, M. Skrede, B. Risberg, C.G. Trope, V.A. Florenes, Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma, Clin. Cancer Res. 9 (2003) 2248-2259.
73. A.C. Porter, R.R. Vaillancourt, Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis, Oncogene 17 (1998) 1343-1352.
74. N. Dunker, K. Krieglstein, Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis, Eur. J. Biochem. 267 (2000) 6982-6988.
75. B.L. Hogan, Bone morphogenetic proteins: multifunctional regulators of vertebrate development, Genes Dev. 10 (1996) 1580-1594.
76. A.K. Hall, R.H. Miller, Emerging roles for bone morphogenetic proteins in central nervous system glial biology, J. Neurosci. Res. 76 (2004) 1-8.
77. L. Yang, TGFbeta and cancer metastasis: an inflammation link, Cancer Metastasis Rev. 29 (2010) 263-271.
78. N.Q. McDonald, W.A. Hendrickson, A structural superfamily of growth factors containing a cystine knot motif, Cell 73 (1993) 421-424.
79. K.A. Waite, C. Eng, From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family, Nat. Rev. Genet. 4 (2003) 763-773.
80. P.M. Siegel, J. Massague, Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer, Nat. Rev. Cancer 3 (2003) 807-821.
81. B. Bierie, H.L. Moses, TGF-beta and cancer, Cytokine Growth Factor Rev. 17 (2006) 29-40.
82. M. Mancino, L. Strizzi, C. Wechselberger, K. Watanabe, M. Gonzales, S. Hamada, N. Normanno, D.S. Salomon, C. Bianco, Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells, J. Cell. Physiol. 215 (2008) 192-203.
83. L. Levy, C.S. Hill, Alterations in components of the TGF-beta superfamily signaling pathways in human cancer, Cytokine Growth Factor Rev. 17 (2006) 41-58.
84. A. Schober, H. Peterziel, C.S. von Bartheld, H. Simon, K. Krieglstein, K. Unsicker, GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action, Neurobiol. Dis. 25 (2007) 378-391.
85. H. Sariola, M. Saarma, Novel functions and signalling pathways for GDNF, J. Cell Sci. 116 (2003) 3855-3862.
86. A. Kritis, D. Kapoukranidou, B. Michailidou, A. Hatzisotiriou, M. Albani, Sciatic nerve crush evokes a biphasic TGF-beta and decorin modulation in the rat spinal cord, Hippokratia 14 (2010) 37-41.
87. A.L. Mead, T.T. Wong, M.F. Cordeiro, I.K. Anderson, P.T. Khaw, Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery, Invest. Ophthalmol. Vis. Sci. 44 (2003) 3394-3401.
88. A. Benigni, C. Zoja, D. Corna, C. Zatelli, S. Conti, M. Campana, E. Gagliardini, D. Rottoli, C. Zanchi, M. Abbate, S. Ledbetter, G. Remuzzi, Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat, J. Am. Soc. Nephrol. 14 (2003) 1816-1824.
89. J.M. Yingling, K.L. Blanchard, J.S. Sawyer, Development of TGF-beta signalling inhibitors for cancer therapy, Nat. Rev. Drug Discov. 3 (2004) 1011-1022.
90. J. Singh, L.E. Ling, J.S. Sawyer, W.C. Lee, F. Zhang, J.M. Yingling, Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5), Curr. Opin. Drug Discov. Devel. 7 (2004) 437-445.
91. F. Gellibert, J. Woolven, M.H. Fouchet, N. Mathews, H. Goodland, V. Lovegrove, A. Laroze, V.L. Nguyen, S. Sautet, R. Wang, C. Janson, W. Smith, G. Krysa, V. Boullay, A.C. De Gouville, S. Huet, D. Hartley, Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors, J. Med. Chem. 47 (2004) 4494-4506.
92. J.S. Sawyer, B.D. Anderson, D.W. Beight, R.M. Campbell, M.L. Jones, D.K. Herron, J.W. Lampe, J.R. McCowan, W.T. McMillen, N. Mort, S. Parsons, E.C. Smith, M. Vieth, L.C. Weir, L. Yan, F. Zhang, J.M. Yingling, Synthesis and activity of new aryland heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain, J. Med. Chem. 46 (2003) 3953-3956.
93. F. Verrecchia, C. Tacheau, E.F. Wagner, A. Mauviel, A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression, J. Biol. Chem. 278 (2003) 1585-1593.
94. D. Kimelman, M. Kirschner, Synergistic induction of mesoderm by FGF and TGFbeta and the identification of an mRNA coding for FGF in the early Xenopus embryo, Cell 51 (1987) 869-877.
95. L. De Moerlooze, B. Spencer-Dene, J.M. Revest, M. Hajihosseini, I. Rosewell, C. Dickson, An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis, Development 127 (2000) 483-492.
96. E. Amaya, T.J. Musci, M.W. Kirschner, Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos, Cell 66 (1991) 257-270.
97. M. Koziczak, T. Holbro, N.E. Hynes, Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins, Oncogene 23 (2004) 3501-3508.
98. J.S. Reis-Filho, P.T. Simpson, N.C. Turner, M.B. Lambros, C. Jones, A. Mackay, A. Grigoriadis, D. Sarrio, K. Savage, T. Dexter, M. Iravani, K. Fenwick, B. Weber, D. Hardisson, F.C. Schmitt, J. Palacios, S.R. Lakhani, A. Ashworth, FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas, Clin. Cancer Res. 12 (2006) 6652-6662.
99. K. Kunii, L. Davis, J. Gorenstein, H. Hatch, M. Yashiro, A. Di Bacco, C. Elbi, B. Lutterbach, FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival, Cancer Res. 68 (2008) 2340-2348.
100. M. Presta, P. Dell'Era, S. Mitola, E. Moroni, R. Ronca, M. Rusnati, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine Growth Factor Rev. 16 (2005) 159-178.
101. M.J. Birrer, M.E. Johnson, K. Hao, K.K. Wong, D.C. Park, A. Bell, W.R. Welch, R.S. Berkowitz, S.C. Mok, Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas, J. Clin. Oncol. 25 (2007) 2281-2287.
102. B. Reuss, O. von Bohlen und Halbach, Fibroblast growth factors and their receptors in the central nervous system, Cell Tissue Res. 313 (2003) 139-157.
103. D. Sarker, R. Molife, T.R. Evans, M. Hardie, C. Marriott, P. Butzberger-Zimmerli, R. Morrison, J.A. Fox, C. Heise, S. Louie, N. Aziz, F. Garzon, G. Michelson, I.R. Judson, D. Jadayel, E. Braendle, J.S. de Bono, A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors, Clin. Cancer Res. 14 (2008) 2075-2081.
104. F. Hilberg, G.J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, W.J. Rettig, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy, Cancer Res. 68 (2008) 4774-4782.
105. J. Chen, B.H. Lee, I.R. Williams, J.L. Kutok, C.S. Mitsiades, N. Duclos, S. Cohen, J. Adelsperger, R. Okabe, A. Coburn, S.Moore, B.J.Huntly, D. Fabbro, K.C. Anderson, J.D. Griffin, D.G. Gilliland, FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies, Oncogene 24 (2005) 8259-8267.
106. J. Matsui, Y. Yamamoto, Y. Funahashi, A. Tsuruoka, T. Watanabe, T. Wakabayashi, T. Uenaka, M. Asada, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition, Int. J. Cancer 122 (2008) 664-671.
107. J. Martinez-Torrecuadrada, G. Cifuentes, P. Lopez-Serra, P. Saenz, A. Martinez, J.I. Casal, Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation, Clin. Cancer Res. 11 (2005) 6280-6290.
108. J. Qing, X. Du, Y. Chen, P. Chan, H. Li, P. Wu, S. Marsters, S. Stawicki, J. Tien, K. Totpal, S. Ross, S. Stinson, D. Dornan, D. French, Q.R. Wang, J.P. Stephan, Y. Wu, C. Wiesmann, A. Ashkenazi, Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice, J. Clin. Invest. 119 (2009) 1216-1229.
109. T.E. Kennedy, T. Serafini, J.R. de la Torre, M. Tessier-Lavigne, Netrins are diffusible chemotropic factors for commissural axons in the embryonic spinal cord, Cell 78 (1994) 425-435.
110. A.W. Puschel, Semaphorins: repulsive guidance molecules show their attractive side, Nat. Neurosci. 2 (1999) 777-778.
111. T. Serafini, T.E. Kennedy, M.J. Galko, C. Mirzayan, T.M. Jessell, M. Tessier-Lavigne, The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans UNC-6, Cell 78 (1994) 409-424.
112. K. Keino-Masu, M. Masu, L. Hinck, E.D. Leonardo, S.S. Chan, J.G. Culotti, M. Tessier-Lavigne, Deleted in colorectal cancer (DCC) encodes a netrin receptor, Cell 87 (1996) 175-185.
113. E.D. Leonardo, L. Hinck, M. Masu, K. Keino-Masu, S.L. Ackerman, M. Tessier-Lavigne, Vertebrate homologues of C. elegans UNC-5 are candidate netrin receptors, Nature 386 (1997) 833-838.
114. A. Chisholm, M. Tessier-Lavigne, Conservation and divergence of axon guidance mechanisms, Curr. Opin. Neurobiol. 9 (1999) 603-615.
115. L. Hinck, The versatile roles of "axon guidance" cues in tissue morphogenesis, Dev. Cell 7 (2004) 783-793.
116. K. Hong, L. Hinck, M. Nishiyama, M.M. Poo, M. Tessier-Lavigne, E. Stein, A ligandgated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion, Cell 97 (1999) 927-941.
117. Y. Jiang, M.T. Liu, M.D. Gershon, Netrins and DCC in the guidance of migrating neural crest-derived cells in the developing bowel and pancreas, Dev. Biol. 258 (2003) 364-384.
118. M. Yebra, A.M. Montgomery, G.R. Diaferia, T. Kaido, S. Silletti, B. Perez, M.L. Just, S. Hildbrand, R. Hurford, E. Florkiewicz, M. Tessier-Lavigne, V. Cirulli, Recognition of the neural chemoattractant Netrin-1 by integrins alpha6beta4 and alpha3-beta1 regulates epithelial cell adhesion and migration, Dev. Cell 5 (2003) 695-707.
119. Y. Liu, E. Stein, T. Oliver, Y. Li, W.J. Brunken, M. Koch, M. Tessier-Lavigne, B.L. Hogan, Novel role for Netrins in regulating epithelial behavior during lung branching morphogenesis, Curr. Biol. 14 (2004) 897-905.
120. M. Koch, J.R. Murrell, D.D. Hunter, P.F. Olson, W. Jin, D.R. Keene, W.J. Brunken, R.E. Burgeson, A novel member of the netrin family, beta-netrin, shares homology with the beta chain of laminin: identification, expression, and functional characterization, J. Cell Biol. 151 (2000) 221-234.
121. X. Lu, F. Le Noble, L. Yuan, Q. Jiang, B. De Lafarge, D. Sugiyama, C. Breant, F. Claes, F. De Smet, J.L. Thomas, M. Autiero, P. Carmeliet, M. Tessier-Lavigne, A. Eichmann, The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system, Nature 432 (2004) 179-186.
122. J.A. Meyerhardt, K. Caca, B.C. Eckstrand, G. Hu, C. Lengauer, S. Banavali, A.T. Look, E.R. Fearon, Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas, Cell Growth Differ. 10 (1999) 35-42.
123. A. Latil, L. Chene, B. Cochant-Priollet, P. Mangin, G. Fournier, P. Berthon, O. Cussenot, Quantification of expression of netrins, slits and their receptors in human prostate tumors, Int. J. Cancer 103 (2003) 306-315.
124. L. Strizzi, C. Bianco, A. Raafat, W. Abdallah, C. Chang, D. Raafat, M. Hirota, S. Hamada, Y. Sun, N. Normanno, R. Callahan, L. Hinck, D. Salomon, Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo, J. Cell Sci. 118 (2005) 4633-4643.
125. M. Mancino, C. Esposito, K. Watanabe, T. Nagaoka, M. Gonzales, C. Bianco, N. Normanno, D.S. Salomon, L. Strizzi, Neuronal guidance protein Netrin-1 induces differentiation in human embryonal carcinoma cells, Cancer Res. 69 (2009) 1717-1721.
126. K. Srinivasan, P. Strickland, A. Valdes, G.C. Shin, L. Hinck, Netrin-1/neogenin interaction stabilizes multipotent progenitor cap cells during mammary gland morphogenesis, Dev. Cell 4 (2003) 371-382.
127. J. Fitamant, C. Guenebeaud, M.M. Coissieux, C. Guix, I. Treilleux, J.Y. Scoazec, T. Bachelot, A. Bernet, P. Mehlen, Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4850-4855.
128. K. Kullander, R. Klein, Mechanisms and functions of Eph and ephrin signalling, Nat. Rev. Mol. Cell Biol. 3 (2002) 475-486.
129. T. Cutforth, L. Moring, M. Mendelsohn, A. Nemes, N.M. Shah, M.M. Kim, J. Frisen, R. Axel, Axonal ephrin-As and odorant receptors: coordinate determination of the olfactory sensory map, Cell 114 (2003) 311-322.
130. B.P. Fox, R.P. Kandpal, Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application, Biochem. Biophys. Res. Commun. 318 (2004) 882-892.
131. E. Pisick, S. Jagadeesh, R. Salgia, Receptor tyrosine kinases and inhibitors in lung cancer, ScientificWorldJournal 4 (2004) 589-604.
132. G. Zeng, Z. Hu, M.S. Kinch, C.X. Pan, D.A. Flockhart, C. Kao, T.A. Gardner, S. Zhang, L. Li, L.A. Baldridge, M.O. Koch, T.M. Ulbright, J.N. Eble, L. Cheng, High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia, Am. J. Pathol. 163 (2003) 2271-2276.
133. D.J. Easty, S.P. Hill, M.Y. Hsu, M.E. Fallowfield, V.A. Florenes, M. Herlyn, D.C. Bennett, Up-regulation of ephrin-A1 during melanoma progression, Int. J. Cancer 84 (1999) 494-501.
134. K.G. Steube, C. Meyer, S. Habig, C.C. Uphoff, H.G. Drexler, Expression of receptor tyrosine kinase HTK (hepatoma transmembrane kinase) and HTK ligand by human leukemia-lymphoma cell lines, Leuk. Lymphoma 33 (1999) 371-376.
135. K. Carles-Kinch, K.E. Kilpatrick, J.C. Stewart, M.S. Kinch, Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior, Cancer Res. 62 (2002) 2840-2847.
136. P.M. Alves, O. Faure, S. Graff-Dubois, D.A. Gross, S. Cornet, S. Chouaib, I. Miconnet, F.A. Lemonnier, K. Kosmatopoulos, EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes, Cancer Res. 63 (2003) 8476-8480.
137. M. Koolpe, M. Dail, E.B. Pasquale, An ephrin mimetic peptide that selectively targets the EphA2 receptor, J. Biol. Chem. 277 (2002) 46974-46979.
138. Y. Luo, D. Raible, J.A. Raper, Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones, Cell 75 (1993) 217-227.
139. B. Kigel, A. Varshavsky, O. Kessler, G. Neufeld, Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells, PLoS One 3 (2008) e3287.
140. E. Castro-Rivera, S. Ran, R.A. Brekken, J.D. Minna, Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells, Cancer Res. 68 (2008) 8295-8303.
141. M. Caunt, J. Mak, W.C. Liang, S. Stawicki, Q. Pan, R.K. Tong, J. Kowalski, C. Ho, H.B. Reslan, J. Ross, L. Berry, I. Kasman, C. Zlot, Z. Cheng, J. Le Couter, E.H. Filvaroff, G. Plowman, F. Peale, D. French, R. Carano, A.W. Koch, Y. Wu, R.J. Watts, M. Tessier-Lavigne, A. Bagri, Blocking neuropilin-2 function inhibits tumor cell metastasis, Cancer Cell 13 (2008) 331-342.
142. N. Leffers, M.J. Gooden, R.A. de Jong, B.N. Hoogeboom, K.A. ten Hoor, H. Hollema, H.M. Boezen, A.G. van der Zee, T. Daemen, H.W. Nijman, Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer, Cancer Immunol. Immunother. 58 (2009) 449-459.
143. J.G. Boyd, T. Gordon, Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury, Mol. Neurobiol. 27 (2003) 277-324.
144. L.F. Lee, J. Guan, Y. Qiu, H.J. Kung, Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase, Mol. Cell. Biol. 21 (2001) 8385-8397.
145. N.C. Spitzer, L.N. Borodinsky, Implications of activity-dependent neurotransmitter-receptor matching, Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 (2008) 1393-1399.
146. K.L. Heffner, T.J. Loving, T.F. Robles, J.K. Kiecolt-Glaser, Examining psychosocial factors related to cancer incidence and progression: in search of the silver lining, Brain Behav. Immun. 17 (Suppl 1) (2003) S109-S111.
147. M.H. Antoni, S.K. Lutgendorf, S.W. Cole, F.S. Dhabhar, S.E. Sephton, P.G. McDonald, M. Stefanek, A.K. Sood, The influence of bio-behavioural factors on tumour biology: pathways and mechanisms, Nat. Rev. Cancer 6 (2006) 240-248.
148. G.P. Chrousos, P.W. Gold, The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis, JAMA 267 (1992) 1244-1252.
149. S.K. Lutgendorf, S. Cole, E. Costanzo, S. Bradley, J. Coffin, S. Jabbari, K. Rainwater, J.M. Ritchie, M. Yang, A.K. Sood, Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines, Clin. Cancer Res. 9 (2003) 4514-4521.
150. S. Ben-Eliyahu, R. Yirmiya, J.C. Liebeskind, A.N. Taylor, R.P. Gale, Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system, Brain Behav. Immun. 5 (1991) 193-205.
151. R. Melamed, E. Rosenne, K. Shakhar, Y. Schwartz, N. Abudarham, S. Ben-Eliyahu, Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor, Brain Behav. Immun. 19 (2005) 114-126.
152. K. Masur, B. Niggemann, K.S. Zanker, F. Entschladen, Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers, Cancer Res. 61 (2001) 2866-2869.
153. G.R. Badino, A. Novelli, C. Girardi, F. Di Carlo, Evidence for functional betaadrenoceptor subtypes in CG-5 breast cancer cell, Pharmacol. Res. 33 (1996) 255-260.
154. B. Marchetti, P.G. Spinola, G. Pelletier, F. Labrie, A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of beta-adrenergic receptors and correlation with tumor growth, J. Steroid Biochem. Mol. Biol. 38 (1991) 307-320.
155. E.K. Sloan, S.J. Priceman, B.F. Cox, S. Yu, M.A. Pimentel, V. Tangkanangnukul, J.M. Arevalo, K. Morizono, B.D. Karanikolas, L. Wu, A.K. Sood, S.W. Cole, The sympathetic nervous system induces a metastatic switch in primary breast cancer, Cancer Res. 70 (2010) 7042-7052.
156. S.Y. Park, J.H. Kang, K.J. Jeong, J. Lee, J.W. Han, W.S. Choi, Y.K. Kim, J. Kang, C.G. Park, H.Y. Lee, Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism, Int. J. Cancer 128 (2011) 2306-2316.
157. K.S. Madden, M.J. Szpunar, E.B. Brown, Beta-Adrenergic Receptors (beta-AR) Regulate VEGF and IL-6 Production by Divergent Pathways in High Beta-ARExpressing Breast Cancer Cell Lines, Breast Cancer Res. Treat. (2011).
158. S.K. Lutgendorf, K. Degeest, L. Dahmoush, D. Farley, F. Penedo, D. Bender, M. Goodheart, T.E. Buekers, L. Mendez, G. Krueger, L. Clevenger, D.M. Lubaroff, A.K. Sood, S.W. Cole, Social Isolation is Associated with Elevated Tumor Norepinephrine in Ovarian Carcinoma Patients, Brain Behav. Immun. 25 (2011) 250-255.
159. H.A. Al-Wadei, M.H. Al-Wadei, H.M. Schuller, Prevention of pancreatic cancer by the beta-blocker propranolol, Anticancer Drugs 20 (2009) 477-482.
160. S. Ganguly, B. Basu, S. Shome, T. Jadhav, S. Roy, J. Majumdar, P.S. Dasgupta, S. Basu, Dopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Kruppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation, Am. J. Pathol. 177 (2010) 2701-2707.
161. D. Chakroborty, C. Sarkar, R.B. Mitra, S. Banerjee, P.S. Dasgupta, S. Basu, Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis, Clin. Cancer Res. 10 (2004) 4349-4356.
162. D. Chakroborty, U.R. Chowdhury, C. Sarkar, R. Baral, P.S. Dasgupta, S. Basu, Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization, J. Clin. Invest. 118 (2008) 1380-1389.
163. S. Basu, J.A. Nagy, S. Pal, E. Vasile, I.A. Eckelhoefer, V.S. Bliss, E.J. Manseau, P.S. Dasgupta, H.F. Dvorak, D. Mukhopadhyay, The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor, Nat. Med. 7 (2001) 569-574.
164. P.S. Wang, A.M. Walker, M.T. Tsuang, E.J. Orav, R.J. Glynn, R. Levin, J. Avorn, Dopamine antagonists and the development of breast cancer, Arch. Gen. Psychiatry 59 (2002) 1147-1154.
165. F.M. Lalonde, M. Myslobodsky, Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson's disease, Breast 12 (2003) 280-282.
166. M. Llovera, C. Pichard, S. Bernichtein, S. Jeay, P. Touraine, P.A. Kelly, V. Goffin, Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation, Oncogene 19 (2000) 4695-4705.
167. C.V. Clevenger, W.P. Chang, W. Ngo, T.L. Pasha, K.T. Montone, J.E. Tomaszewski, Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop, Am. J. Pathol. 146 (1995) 695-705.
168. L.F. Mohammad-Zadeh, L. Moses, S.M. Gwaltney-Brant, Serotonin: a review, J. Vet. Pharmacol. Ther. 31 (2008) 187-199.
169. F. Cote, E. Thevenot, C. Fligny, Y. Fromes, M. Darmon, M.A. Ripoche, E. Bayard, N. Hanoun, F. Saurini, P. Lechat, L.Dandolo,M.Hamon, J.Mallet,G. Vodjdani, Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13525-13530.
170. M. Lesurtel, C. Soll, R. Graf, P.A. Clavien, Role of serotonin in the hepatogastroIntestinal tract: an old molecule for new perspectives, Cell. Mol. Life Sci. 65 (2008) 940-952.
171. J. Russo, I.H. Russo, Toward a physiological approach to breast cancer prevention, Cancer Epidemiol. Biomarkers Prev. 3 (1994) 353-364.
172. E. Mallon, P. Osin, N. Nasiri, I. Blain, B. Howard, B. Gusterson, The basic pathology of human breast cancer, J. Mammary Gland Biol. Neoplasia 5 (2000) 139-163.
173. M.A. Stull, V. Pai, A.J. Vomachka, A.M. Marshall, G.A. Jacob, N.D. Horseman, Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16708-16713.
174. V.P. Pai, A.M. Marshall, L.L. Hernandez, A.R. Buckley, N.D. Horseman, Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival, Breast Cancer Res. 11 (2009) R81.
175. M. Marzioni, S. Glaser, H. Francis, L. Marucci, A. Benedetti, D. Alvaro, S. Taffetani, Y. Ueno, T. Roskams, J.L. Phinizy, J. Venter, G. Fava, G.D. Lesage, G. Alpini, Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin, Gastroenterology 128 (2005) 121-137.
176. L.M. Vicentini, M.G. Cattaneo, R. Fesce, Evidence for receptor subtype cross-talk in the mitogenic action of serotonin on human small-cell lung carcinoma cells, Eur. J. Pharmacol. 318 (1996) 497-504.
177. E.J. Siddiqui, M. Shabbir, D.P. Mikhailidis, C.S. Thompson, F.H. Mumtaz, The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation, J. Urol. 176 (2006) 1648-1653.
178. A. Suzuki, S. Naruse, M. Kitagawa, H. Ishiguro, T. Yoshikawa, S.B. Ko, A. Yamamoto, H. Hamada, T. Hayakawa, 5-hydroxytryptamine strongly inhibits fluid secretion in guinea pig pancreatic duct cells, J. Clin. Invest. 108 (2001) 749-756.
179. L.G. Huggins, L.V. Davis, Adjuvant and novel anti-cancer drug, keyhole limpet hemocyanin, targets serotonin signaling pathway by inhibiting feeding, locomotion and egg laying in C. elegans, The FASEB Journal (2008) http://www.fasebj.org/cgi/content/meeting_abstract/22/1_MeetingAbstracts/748.13.
180. R.E. Kast, Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines, Br. J. Pharmacol. 161 (2010) 481-487.
181. C. Gotti, D. Fornasari, F. Clementi, Human neuronal nicotinic receptors, Prog. Neurobiol. 53 (1997) 199-237.
182. H.M. Schuller, Cell type specific, receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines, Biochem. Pharmacol. 38 (1989) 3439-3442.
183. S. Trombino, A. Cesario, S. Margaritora, P. Granone, G. Motta, C. Falugi, P. Russo, Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway, Cancer Res. 64 (2004) 135-145.
184. H.P. Wong, L. Yu, E.K. Lam, E.K. Tai, W.K. Wu, C.H. Cho, Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholaminesynthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells, Toxicol. Appl. Pharmacol. 221 (2007) 261-267.
185. V.Y. Shin, H.C. Jin, E.K. Ng, C.H. Cho, W.K. Leung, J.J. Sung, K.M. Chu, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone promoted gastric cancer growth through prostaglandin E receptor (EP2 and EP4) in vivo and in vitro, Cancer Sci. 102 (2011) 926-33.
186. P. Song, H.S. Sekhon, X.W. Fu, M. Maier, Y. Jia, J. Duan, B.J. Proskosil, C. Gravett, J. Lindstrom, G.P. Mark, S. Saha, E.R. Spindel, Activated cholinergic signaling provides a target in squamous cell lung carcinoma, Cancer Res. 68 (2008) 4693-4700.
187. J.I. Ukegawa, Y. Takeuchi, S. Kusayanagi, K. Mitamura, Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells, J. Cancer Res. Clin. Oncol. 129 (2003) 272-278.
188. E. Jimenez, M. Montiel, Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells, J. Cell. Physiol. 204 (2005) 678-686.
189. L. Paleari, A. Cesario, M. Fini, P. Russo, Alpha7-nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? Drug Discov. Today 14 (2009) 822-836.
190. A.M. Tata, Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy, Recent Pat. CNS Drug Discov. 3 (2008) 94-103.
191. P. Song, H.S. Sekhon, A. Lu, J. Arredondo, D. Sauer, C. Gravett, G.P. Mark, S.A. Grando, E.R. Spindel, M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion, Cancer Res. 67 (2007) 3936-3944.
192. J.C. Watkins, R.H. Evans, Excitatory amino acid transmitters, Annu. Rev. Pharmacol. Toxicol. 21 (1981) 165-204.
193. E. Hinoi, T. Takarada, T. Ueshima, Y. Tsuchihashi, Y. Yoneda, Glutamate signaling in peripheral tissues, Eur. J. Biochem. 271 (2004) 1-13.
194. R. Pacheco, T. Gallart, C. Lluis, R. Franco, Role of glutamate on T-cell mediated immunity, J. Neuroimmunol. 185 (2007) 9-19.
195. E.A. Cavalheiro, J.W. Olney, Glutamate antagonists: deadly liaisons with cancer, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5947-5948.
196. N. Kalariti, N. Pissimissis, M. Koutsilieris, The glutamatergic system outside the CNS and in cancer biology, Expert Opin. Investig. Drugs 14 (2005) 1487-1496.
197. B.C. Yoo, E. Jeon, S.H. Hong, Y.K. Shin, H.J. Chang, J.G. Park, Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line, Clin. Cancer Res. 10 (2004) 4176-4184.
198. H.J. Chang, B.C. Yoo, S.B. Lim, S.Y. Jeong, W.H. Kim, J.G. Park, Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance, Clin. Cancer Res. 11 (2005) 3288-3295.
199. E. Aronica, B. Yankaya, G.H. Jansen, S. Leenstra, C.W. van Veelen, J.A. Gorter, D. Troost, Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy, Neuropathol. Appl. Neurobiol. 27 (2001) 223-237.
200. J.F. de Groot, Y. Piao, L. Lu, G.N. Fuller, W.K. Yung, Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation, J. Neurooncol. 88 (2008) 121-133.
201. S. Ishiuchi, K. Tsuzuki, Y. Yoshida, N. Yamada, N. Hagimura, H. Okado, A. Miwa, H. Kurihara, Y. Nakazato, M. Tamura, T. Sasaki, S. Ozawa, Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells, Nat. Med. 8 (2002) 971-978.
202. J.W. Liu, M.S. Kim, J. Nagpal, K. Yamashita, L. Poeta, X. Chang, J. Lee, H.L. Park, C. Jeronimo, W.H. Westra, M. Mori, C. Moon, B. Trink, D. Sidransky, Quantitative hypermethylation of NMDAR2B in human gastric cancer, Int. J. Cancer 121 (2007) 1994-2000.
203. M. Abdul, N. Hoosein, N-methyl-D-aspartate receptor in human prostate cancer, J. Membr. Biol. 205 (2005) 125-128.
204. S.Y. Park, S.A. Lee, I.H. Han, B.C. Yoo, S.H. Lee, J.Y. Park, I.H. Cha, J. Kim, S.W. Choi, Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma, Oncol. Rep. 17 (2007) 81-87.
205. Y.E. Marin, S. Chen, Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development, J. Mol. Med. 82 (2004) 735-749.
206. P.M. Pollock, K. Cohen-Solal, R. Sood, J. Namkoong, J.J.Martino, A. Koganti, H. Zhu, C. Robbins, I. Makalowska, S.S. Shin, Y. Marin, K.G. Roberts, L.M. Yudt, A. Chen, J. Cheng, A. Incao,H.W. Pinkett, C.L. Graham,K.Dunn, S.M. Crespo-Carbone,K.R.Mackason, K.B. Ryan, D. Sinsimer, J. Goydos, K.R. Reuhl, M. Eckhaus, P.S. Meltzer, W.J. Pavan, J.M. Trent, S. Chen, Melanomamouse model implicates metabotropic glutamate signaling in melanocytic neoplasia, Nat. Genet. 34 (2003) 108-112.
207. S.W. Choi, S.Y. Park, S.P. Hong, H. Pai, J.Y. Choi, S.G. Kim, The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma, J. Oral Pathol. Med. 33 (2004) 533-537.
208. L. Iacovelli, A. Arcella, G. Battaglia, S. Pazzaglia, E. Aronica, P. Spinsanti, A. Caruso, E. De Smaele, A. Saran, A. Gulino, M. D'Onofrio, F. Giangaspero, F. Nicoletti, Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas, J. Neurosci. 26 (2006) 8388-8397.
209. M.T. Bianchi, L. Song, H. Zhang, R.L. Macdonald, Two different mechanisms of disinhibition produced by GABAA receptor mutations linked to epilepsy in humans, J. Neurosci. 22 (2002) 5321-5327.
210. A. Jansen, M. Hoepfner, K.H. Herzig, E.O. Riecken, H. Scherubl, GABA(C) receptors in neuroendocrine gut cells: a new GABA-binding site in the gut, Pflugers Arch. 441 (2000) 294-300.
211. G. Glassmeier, K.H. Herzig, M. Hopfner, K. Lemmer, A. Jansen, H. Scherubl, Expression of functional GABAA receptors in cholecystokinin-secreting gut neuroendocrine murine STC-1 cells, J. Physiol. 510 (Pt 3) (1998) 805-814.
212. F. Entschladen, M. Gunzer, C.M. Scheuffele, B. Niggemann, K.S. Zanker, T lymphocytes and neutrophil granulocytes differ in regulatory signaling and migratory dynamics with regard to spontaneous locomotion and chemotaxis, Cell. Immunol. 199 (2000) 104-114.
213. K. Szczaurska, M. Mazurkiewicz, A. Opolski, The role of GABA-ergic system in carcinogenesis, Postepy Hig. Med. Dosw. 57 (2003) 485-500.
214. M. Watanabe, K. Maemura, K. Oki, N. Shiraishi, Y. Shibayama, K. Katsu, Gammaaminobutyric acid (GABA) and cell proliferation: focus on cancer cells, Histol. Histopathol. 21 (2006) 1135-1141.
215. H.M. Schuller, H.A. Al-Wadei, M. Majidi, GABA B receptor is a novel drug target for pancreatic cancer, Cancer 112 (2008) 767-778.
216. M. Matuszek, M. Jesipowicz, Z. Kleinrok, GABA content and GAD activity in gastric cancer, Med. Sci. Monit. 7 (2001) 377-381.
217. M. Mazurkiewicz, A. Opolski, J. Wietrzyk, C. Radzikowski, Z. Kleinrok, GABA level and GAD activity in human and mouse normal and neoplastic mammary gland, J. Exp. Clin. Cancer Res. 18 (1999) 247-253.
218. M.S. Moon, E.W. Cho, H.S. Byun, I.L. Jung, I.G. Kim, GAD 67KD antisense in colon cancer cells inhibits cell growth and sensitizes to butyrate and pH reduction and H2O2 and gamma-radiation, Arch. Biochem. Biophys. 430 (2004) 229-236.
219. C.S. Nicholson-Guthrie, G.D. Guthrie, G.P. Sutton, J.C. Baenziger, Urine GABA levels in ovarian cancer patients: elevated GABA in malignancy, Cancer Lett. 162 (2001) 27-30.
220. M. Zafrakas, M. Chorovicer, I. Klaman, G. Kristiansen, P.J. Wild, U. Heindrichs, R. Knuchel, E. Dahl, Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue, Int. J. Cancer 118 (2006) 1453-1459.
221. S.K. Johnson, R.S. Haun, The gamma-aminobutyric acid A receptor pi subunit is overexpressed in pancreatic adenocarcinomas, JOP 6 (2005) 136-142.
222. T. Wang, W. Huang, F. Chen, Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo, Life Sci. 82 (2008) 536-541.
223. E. Rozengurt, Early signals in the mitogenic response, Science 234 (1986) 161-166.
224. V. Almendro, S. Garcia-Recio, P. Gascon, Tyrosine kinase receptor transactivation associated to G protein-coupled receptors, Curr. Drug Targets 11 (2010) 1169-1180.
225. L.E. Heasley, Autocrine and paracrine signaling through neuropeptide receptors in human cancer, Oncogene 20 (2001) 1563-1569.
226. C. Palma, Tachykinins and their receptors in human malignancies, Curr. Drug Targets 7 (2006) 1043-1052.
227. A. Eglezos, P.V. Andrews, R.L. Boyd, R.D. Helme, Modulation of the immune response by tachykinins, Immunol. Cell Biol. 69 (Pt 4) (1991) 285-294.
228. K.L. Bost, Tachykinin-mediated modulation of the immune response, Front. Biosci. 9 (2004) 3331-3332.
229. A.S. Singh, A. Caplan, K.E. Corcoran, J.S. Fernandez, M. Preziosi, P. Rameshwar, Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes, Vascul. Pharmacol. 45 (2006) 235-242.
230. T.A. Castro, M.C. Cohen, P. Rameshwar, The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential, Clin. Exp. Metastasis 22 (2005) 621-628.
231. G. Rao, P.S. Patel, S.P. Idler, P. Maloof, P. Gascon, J.A. Potian, P. Rameshwar, Facilitating role of preprotachykinin-I gene in the integration of breast cancer cells within the stromal compartment of the bone marrow: a model of early cancer progression, Cancer Res. 64 (2004) 2874-2881.
232. D. Singh, D.D. Joshi, M. Hameed, J. Qian, P. Gascon, P.B. Maloof, A. Mosenthal, P. Rameshwar, Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 388-393.
233. S.C. Huang, V.L. Korlipara, Neurokinin-1 receptor antagonists: a comprehensive patent survey, Expert Opin. Ther. Pat. 20 (2010) 1019-1045.
234. C. Mayordomo, S. Garcia-Recio, E. Ametller, P. Fernandez-Nogueira, I.Casas, E. Pastor-Arroyo, P. Gascón, V. Almendro, Targeting of Substance P induces cancer cell death and decreases the steady-state of EGFR and Her2, submitted for publication.
235. S.D. Brain, Sensory neuropeptides: their role in inflammation and wound healing, Immunopharmacology 37 (1997) 133-152.
236. F. Entschladen, K. Lang, T.L. Drell, J. Joseph, K.S. Zaenker, Neurotransmitters are regulators for the migration of tumor cells and leukocytes, Cancer Immunol. Immunother. 51 (2002) 467-482.
237. A.V. Delgado, A.T. McManus, J.P. Chambers, Exogenous administration of substance P enhances wound healing in a novel skin-injury model, Exp. Biol. Med. (Maywood) 230 (2005) 271-280.
238. Z. Khalil, R. Helme, Sensory peptides as neuromodulators of wound healing in aged rats, J. Gerontol. A Biol. Sci. Med. Sci. 51 (1996) B354-B361.
239. N. Zhang, J.J. Oppenheim, Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems, J. Leukoc. Biol. 78 (2005) 1210-1214.
240. J.J. Watson, S.J. Allen, D. Dawbarn, Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22 (2008) 349-359.
241. J.M. Jimenez-Andrade, A.P. Bloom, J.I. Stake, W.G. Mantyh, R.N. Taylor, K.T. Freeman, J.R. Ghilardi, M.A. Kuskowski, P.W. Mantyh, Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain, J. Neurosci. 30 (2010) 14649-14656.